AERI - Aerie Pharmaceuticals Non-GAAP EPS of -$0.66 misses by $0.01 revenue of $29.83M misses by $0.07M
Aerie Pharmaceuticals press release (NASDAQ:AERI): Q1 Non-GAAP EPS of -$0.66 misses by $0.01. Revenue of $29.83M (+29.9% Y/Y) misses by $0.07M. Reaffirms 2022 Glaucoma Franchise Guidance of $130 Million to $140 Million. Cash, cash equivalents and total investments were $199.2 million as of March 31, 2022 compared to $139.8 million as of December 31, 2021.
For further details see:
Aerie Pharmaceuticals Non-GAAP EPS of -$0.66 misses by $0.01, revenue of $29.83M misses by $0.07M